Clinical experience with famciclovir against hepatitis B virus

Intervirology

Volumn 40, Issue 5-6, 1997, Pages 337-342

  Bartholomeusz, Angeline ^a   Groenen, Leo C ^b   Locarnini, Stephen A ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Famciclovir; Hepatitis B virus; Penciclovir; Polymerase

Indexed keywords

FAMCICLOVIR; RNA DIRECTED RNA POLYMERASE;

ARTICLE; HEPATITIS B; LIVER; MUTATION RATE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS INFECTION; VIRUS REPLICATION;

2-AMINOPURINE; ADMINISTRATION, ORAL; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; GENES, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER TRANSPLANTATION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PRODRUGS; RNA-DIRECTED DNA POLYMERASE;

EID: 2642679257     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150566     Document Type: Article

References (40)

1. Kane MA: Global status of hepatitis B immunisation, Lancet 1996;348:696.
2. Lok ASF: Natural history and control of peri-natally acquired hepatitis B virus infection, DigDis 1992;10:46-52.
3. Hadziyannis SJ: Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment, Viral Hepatitis Rev 1995:1:7-36.
4. Lok ASF: Treatment of chronic hepatitis, J Viral Hepatitis 1994:1:105-124.
5. Hoofnagle JH, Di Bisceglie AM: Drug Therapy: The treatment of chronic viral hepatitis, N Engl J Med 1997;336:347-356.
6. Luscombe CA, Locarnini SA: The mechanism of action of antiviral agents in chronic hepatitis B, Viral Hepatitis Rev 1996:2:1-35.
7. Verc Hodge RA: Review: Antiviral portraits series, number 3. Famciclovir and penciclovir, The mode of action of famciclovir including its conversion to penciclovir, Antiviral Chcm Chcmother 1993:4:67-84.
8. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S: In vitro antiviral activity of penciclovir, a novel purine nucleoside against duck hepatitis B virus, Antimicrob Agents Chemother 1994:38:719-723.
9. Shaw T, Mok SS, Locarnini SA: Inhibition of hepatitis B virus DNA polymerase by cnan-tiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir, Hepatologv 1996; 24:996-1002.
10. Tsiquaye KN, Slomka MJ, Maung M: Oral famciclovir against duck hepatitis B virus replication in hepatic and non-hepatic tissues of duckling infected, J Med Virol 1994:42:306-310.
11. Ling R, Mutimer D, Ahmed M, Boxall EH, Ealls E, Dusheiko GM, Harrison T: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudinc, flepatology 1996:24:711-713.
12. Dean J, Bowden S, Locarnini S: Reversion of duck hepatitis B DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir, Antiviral Res 1995: 27:171-178.
13. Bbker KHW, Ringe B, Kruger M, Pichlmayr R, Manns MP: Prostaglandin E plus famciclovir: A new concept for the treatment of severe hepatitis B after liver transplantation, Transplantation 1994:57:1706-1708.
14. Kruger T, Tillman HL, Tratuwein C, Oldhafer K, Bokcr KHW, Pichlmeyer R, Manns MP: Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation, Ilepatology 1995:22:219A.
15. Main J, Brown JL, Howells C, Galassini R, Crossey M, Karaviannis P, Georgiou P, Atkinson G, Thomas HC: A double-blind placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection, J Viral Hepatitis 1996:3:211-215.
16. Trepo C, Jezck P, Atkinson GE, Boon RJ: Efficacy of famciclovir in chronic hepatitis B: Results of a dose finding study, Hepatologv 1996: 24:188A.
17. Summers J, Mason W: Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate, Cell 1982; 29:403-415.
18. Radizwell G, Tucker W, Schallcr H: Mutational analysis of the hepatitis B virus P gene product domain structure and RNase H activity, J Virol 1990;64:613-620.
19. Poch O, Sauvagct I, Delarue M, Tordo N: Identification of four conserved motifs among the RNA dependent polymerase encoding elements, EMBOJ 1989:8:3867-3874.
20. Delarue M, Poch O, Tordo T, Moras D, Argos P: An attempt to unify the structure of polymerases, Protein Eng 1990:3:461-467.
21. Toll H, Hayashida H, MiyataT: Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus, Nature 1983;305:827-829.
22. Sawaya MR, Pelletier H, Kumar A, Wilson SH, Kraut J: Crystal structure of rat DNA polymerase beta: Evidence for a common polymerase mechanism, Science 1994:264:1930-1935.
23. Jocobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Liu X, Tantillo C, Williams RL, Kamcr G, Ferris AL, Clark P: Crystal structure of human immunodeficiency virus type I reverse transcriptase complcxcd with double-stranded DNA at 3.0 A resolution shows bent DNA, Proc Natl Acad Sci USA 1993:90:6320-6324.
24. Nanni RG, Ding J, Jacobo-Molina A, Hughes S, Arnold E: Review of HIV-I reverse transcriptase three dimensional structure: Implications for drug design, Perspect Drug Discovery Design 1993:1:129-150.
25. Gironcs R, Miller RH: Mutation rate of the hcpadna virus genome, Virology 1989:170: 595-597.
26. Aye TT, Bartholomeusz A, Shaw T, Brcschkin A, Groenen L, Bowden S, McMillan J, Angus P, McCaughan GW, Locarnini S: Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation, Hepatology 1996:24:285A.
27. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, Locarnini S: Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation, J Hepatol 1997:26:1148-1153.
28. Bartholomew MM, Jansen RW, Jeffers U, Reddy KR, Johnson LC, Bunzendahl H, Con-dreay LD, Tzakis AG, Schiff ER, Brown NA: Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation, Lancet 1997:349:20-22.
29. De Man RA, Bartholomeusz A, Locarnini S, Niesters HGM, Zondervan PE: The occurrence of sequential viral mutations in a liver transplant recipient re-infected with hepatitis B: Primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudinc resistance, J Hepatol 1997:26(suppl 1):77.
30. Lai CL, Liaw YF, Leung N, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent I, Gray DF: A 12 month course of lamivudine (100 mg od) therapy improves liver histology: Results of a placebo controlled multicenire study in Asia, J Hepatol 1997;26(suppl 1):79.
31. Naoumov NV, Chokshi S, Smith H, Williams R: Emergence and characterisation of lamivu-dinc-resistant hepatitis B virus variant, Hepa-tology J 1996;24:282A.
32. Tillman HL, Trautwcin C, Kruger M, Bdker K, Schlitt MJ, Condreay L, Dcslauriars M, Bruns I, Pichlmayr R, Manns MP: Inhibition of hepatitis B virus replication with lamivudinc in patients previously treated with famciclovir after liver transplantation, J Hepatol 1997;26(suppl 1): 153.
33. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL: Mutation in HBV RNA-depcndenl DNA polymerase confers resistance to lamivudinc in vivo, Hepatology 1996;24:714-717.
34. Tisdale M, Kemp SF, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase, Proc Natl Acad SciUSA 1993:90:5653-5656.
35. Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksov N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW: Characterization of human immunodeficiency viruses resistant to oxathiolanc-cytosine nucleosides, Antimi-crob Agents Chemother 1993:7:875-881.
36. Mellors JW, Bazmi HZ, Schinazi RF, Roy BM, Hsiou Y, Arnold E, Weir J, Mayers DL: Novel mutations in reverse transcriptase of human immunodeficiency virus type I reduce susceptibility to I'oscamct in laboratory and clinical isolates, Antimicrob Agents Chemother 1995; 39:1087-1092.
37. Ucno T, Shirasaka T, Mitsuya H: Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynuclcoside 5'-triphos-phatcs, J Biol Chcm 1995:270:23605-23611.
38. lversen AK, Shafer RW', Wchrly K, Winters MA, Mullins JI, Chescbro B, Mcrigan TC: Mul-tidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy, J Virol 1996:70:1086-1090.
39. Shirasaka T, Kavlick MF, Ucno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R: Emergence of human immunodeficiency virus type I variants with resistance to multiple dideoxynucleosides in patients receiving therapy with didcoxvnu-cleosides, Proc Natl Acad Sci USA 1995:92: 2398-2402.
40. Chiou HC, Kumura K, Hu A, Kerns KM, Coen DMM: Penciclovir-resistance mutations in the herpes simplex virus DNA polymerase gene, Antiviral Chem Chemother 1995:6:281-288.